WAVE Life Sciences (WVE)
(Real Time Quote from BATS)
$6.79 USD
-0.17 (-2.44%)
Updated Sep 19, 2025 03:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
WVE 6.79 -0.17(-2.44%)
Will WVE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for WVE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WVE
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
WVE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates
Other News for WVE
WVE forms Narrow Range Bar on September 19
The technical outlook for WVE is unchanged after it falls 0.29% on September 18
WVE forms Narrow Range Bar on September 16
Narrow Range Bar appears for WVE after 0.0% move
Is WVE compressing before expansion? NR7 shows up after sinking 2.65%